Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,822 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.
Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Akahoshi T, Maehara Y, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: satoh t. J Gastroenterol Hepatol. 2014 Sep;29(9):1728-35. doi: 10.1111/jgh.12619. J Gastroenterol Hepatol. 2014. PMID: 24731162 Clinical Trial.
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C.
Kainuma M, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Shimono J, Shimoda S, Hayashi J; Kyushu University Liver Disease Study Group. Kainuma M, et al. Among authors: satoh t. World J Gastroenterol. 2010 Sep 21;16(35):4400-9. doi: 10.3748/wjg.v16.i35.4400. World J Gastroenterol. 2010. PMID: 20845506 Free PMC article. Clinical Trial.
Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B.
Tamada Y, Yatsuhashi H, Masaki N, Nakamuta M, Mita E, Komatsu T, Watanabe Y, Muro T, Shimada M, Hijioka T, Satoh T, Mano Y, Komeda T, Takahashi M, Kohno H, Ota H, Hayashi S, Miyakawa Y, Abiru S, Ishibashi H. Tamada Y, et al. Among authors: satoh t. Gut. 2012 May;61(5):765-73. doi: 10.1136/gutjnl-2011-300832. Epub 2011 Nov 7. Gut. 2012. PMID: 22068163
Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study [KULDS] Group. Ogawa E, et al. Among authors: satoh t. J Gastroenterol Hepatol. 2012 Jul;27(7):1233-40. doi: 10.1111/j.1440-1746.2011.06965.x. J Gastroenterol Hepatol. 2012. PMID: 22098185 Clinical Trial.
Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase.
Kainuma M, Furusyo N, Azuma K, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Kainuma M, et al. Among authors: satoh t. Hepatol Res. 2012 Jan;42(1):33-41. doi: 10.1111/j.1872-034X.2011.00907.x. Epub 2011 Nov 22. Hepatol Res. 2012. PMID: 22103907
An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study Group. Ogawa E, et al. Among authors: satoh t. J Infect Chemother. 2012 Oct;18(5):689-97. doi: 10.1007/s10156-012-0396-5. Epub 2012 Mar 27. J Infect Chemother. 2012. PMID: 22450877
Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B.
Toyama T, Ishida H, Ishibashi H, Yatsuhashi H, Nakamuta M, Shimada M, Ohta H, Satoh T, Kato M, Hijioka T, Takano H, Komeda T, Yagura M, Mano H, Watanabe Y, Kobayashi M, Mita E. Toyama T, et al. Among authors: satoh t. Hepatol Res. 2012 Dec;42(12):1168-74. doi: 10.1111/j.1872-034X.2012.01038.x. Epub 2012 May 17. Hepatol Res. 2012. PMID: 22594879
Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: satoh t. J Hepatol. 2013 Mar;58(3):495-501. doi: 10.1016/j.jhep.2012.10.017. Epub 2012 Oct 23. J Hepatol. 2013. PMID: 23099187
3,822 results